CD82 and prostate carcinoma: CD82 expressions were obviously decreased in prostate cancer cells (LNCaP, C4-2, C4-2B, PC-3, DU145, and CWR22Rv1) compared with prostate normal epithelia cell RWPE-1 and benign prostatic hyperplasia cell BPH-1 by real-time PCR and Western blot (Figure 1(b)).